Division of Surgery and Cancer Medicine

Fingerprint The fingerprint is based on mining the text of the scientific documents related to the associated persons. Based on that an index of weighted terms is created, which defines the key subjects of research unit

Lymphoma Medicine & Life Sciences
B-Cell Lymphoma Medicine & Life Sciences
Lymphoma, Large B-Cell, Diffuse Medicine & Life Sciences
Hodgkin Disease Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Non-Hodgkin's Lymphoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Research Output 1978 2011

301 Citations

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

Pfreundschuh, M., Kuhnt, E., Trümper, L., Österborg, A., Trneny, M., Shepherd, L., Gill, D. S., Walewski, J., Pettengell, R., Jaeger, U., Zinzani, P. L., Shpilberg, O., Kvaloy, S., de Nully Brown, P., Stahel, R., Milpied, N., López-Guillermo, A., Poeschel, V., Grass, S., Loeffler, M. & 1 othersMurawski, N., Oct 1 2011, In : The lancet oncology. 12, 11, p. 1013-1022 10 p.

Research output: Contribution to journalArticle

Lymphoma, Large B-Cell, Diffuse
Drug Therapy
Disease-Free Survival
Rituximab
Intention to Treat Analysis
104 Citations

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study

Pfreundschuh, M., Ho, A. D., Cavallin-Stahl, E., Wolf, M., Pettengell, R., Vasova, I., Belch, A., Walewski, J., Zinzani, P. L., Mingrone, W., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Corrado, C., Scheliga, A., Loeffler, M. & Kuhnt, E., May 1 2008, In : The Lancet Oncology. 9, 5, p. 435-444 10 p.

Research output: Contribution to journalArticle

Lymphoma, Large B-Cell, Diffuse
Drug Therapy
Neoplasms
Survival
Intention to Treat Analysis
1338 Citations

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

Pfreundschuh, M., Trümper, L., Österborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P. L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., López-Guillermo, A., Corrado, C., Scheliga, A., Milpied, N. & 4 othersMendila, M., Rashford, M., Kuhnt, E. & Loeffler, M., May 1 2006, In : Lancet Oncology. 7, 5, p. 379-391 13 p.

Research output: Contribution to journalArticle

Lymphoma, Large B-Cell, Diffuse
Randomized Controlled Trials
Drug Therapy
Disease-Free Survival
Survival